Could 'Peacekeeper' cells free liver transplant patients from lifelong drugs?

NCT ID NCT03577431

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether infusing specially grown donor-specific regulatory T cells (Tregs) can allow liver transplant recipients to safely reduce or stop their anti-rejection medications. Nine participants will receive a single dose of these cells and be monitored for side effects and whether they can maintain a healthy liver without standard immunosuppression. The goal is to see if this cellular therapy can induce 'operational tolerance'—a state where the body accepts the donor organ without needing lifelong drugs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor-specific regulatory T cells (arTreg-CSB)
What this could lead to
If successful, this could allow some liver transplant recipients to stop or reduce lifelong anti-rejection medication without rejecting the organ.
What could go wrong
This is a very early, tiny trial (9 people) focused on safety, not proof of effectiveness. The approach may not work or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END STAGE LIVER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Massachusetts General Hospital: Transplantation

    Boston, Massachusetts, 02114, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.